Morgan Stanley Smith Barney LLC Form 8.3 - XERIS PHARMACEUTICALS INC (6277M)
September 22 2021 - 7:18AM
UK Regulatory
TIDM0A8E
RNS Number : 6277M
Morgan Stanley Smith Barney LLC
22 September 2021
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES
REPRESENTING 1% OR MORE
1. KEY INFORMATION
Name of person dealing Morgan Stanley Smith Barney
(Note 1) LLC
Company dealt in XERIS PHARMACEUTICALS INC
===========================
Class of relevant security $0.001 COMMON STOCK
to which the dealings
being disclosed relate
(Note 2)
===========================
Date of dealing 21 September 2021
===========================
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security
dealt in ( Note 3)
Long Short
Number (%) Number (%)
=========== ===== =========== ======
(1) Relevant securities 13,204 0.02 0 0.00
=========== ====== =========== =======
(2)Derivatives (other
than options) 0 0.00 0 0.00
=========== ====== =========== =======
(3)Options and agreements
to purchase/sell 0 0.00 0 0.00
=========== ====== =========== =======
Total 13,204 0.02 0 0.00
=========== ====== =========== =======
(b) Interests and short positions in relevant securities of the company, other than the
class dealt in ( Note 3 )
Class of relevant security: Long Short
Number (%) Number (%)
=========== ===== =========== ======
(1) Relevant securities 0 0.00 0 0.00
=========== ====== =========== =======
(2)Derivatives (other
than options) 0 0.00 0 0.00
=========== ====== =========== =======
(3)Options and agreements
to purchase/sell 0 0.00 0 0.00
=========== ====== =========== =======
Total 0 0.00 0 0.00
=========== ====== =========== =======
1. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale Number of relevant securities Price per unit
(Note 5)
SALE 61 2.4311 USD
==================================== ===================
(b) Derivatives transactions (other than options transactions)
Product Nature of transaction Number of relevant Price per
name, (Note 6) securities unit
e.g. CFD (Note 7) (Note 5)
N/A N/A N/A N/A
====================== =================== ==========
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product Writing, Number Exercise Type, Expiry Option money
name, selling, of securities price e.g. date paid/received
e.g. purchasing, to which American, per unit
call varying the option European (Note 5)
option etc. relates etc.
(Note 7)
N/A N/A N/A N/A N/A N/A N/A
============ ============== ======== ========== ====== ==============
(ii) Exercising
Product name, Number of securities Exercise price
e.g. call option per unit (Note
5)
N/A N/A N/A
=========================== ====================
(d) Other dealings (including transactions in respect of new
securities) (Note 4)
Nature of transaction Details Price per unit
(Note 8) (if applicable)
(Note 5)
N/A N/A N/A
============== =====================
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options
or derivatives
Full details of any agreement, arrangement or
understanding between the person disclosing and
any other person relating to the voting rights
of any relevant securities under any option referred
to on this form or relating to the voting rights
or future acquisition or disposal of any relevant
securities to which any derivative referred to
on this form is referenced. If none, this should
be stated.
NONE
Is a Supplemental Form 8 attached? (Note 9) NO
Date of disclosure 22 September 2021
Contact name Craig Horsley
=================
Telephone number +44 141 245-7736
=================
If a connected EFM, name N/A
of offeree/offeror with
which connected
=================
If a connected EFM, state N/A
nature of connection (Note
10)
=================
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ISEMZGZLMZVGMZM
(END) Dow Jones Newswires
September 22, 2021 07:18 ET (11:18 GMT)
Xeris Biopharma (LSE:0A8E)
Historical Stock Chart
From Oct 2024 to Nov 2024
Xeris Biopharma (LSE:0A8E)
Historical Stock Chart
From Nov 2023 to Nov 2024
